{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:14:08Z","timestamp":1788246848406,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsches Krebsforschungszentrum (DKFZ)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostate-specific membrane antigen-targeted radioligand therapy (PSMA-RLT) demonstrates clinical efficacy in metastatic castration-resistant prostate cancer (mCRPC), yet robust biomarkers for dynamic treatment monitoring and resistance remain lacking. We investigated circulating tumor DNA (ctDNA)-derived tumor fraction (TFx) and genome-wide copy-number alterations (CNAs) as non-invasive biomarkers of treatment response and resistance biology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Seventy-eight patients with advanced mCRPC receiving tandem [\n                      <jats:sup>225<\/jats:sup>\n                      Ac]Ac-\/[\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 were prospectively enrolled. Plasma samples collected longitudinally (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009172) underwent ultra\u2013low-pass whole-genome sequencing. TFx was estimated using ichorCNA, and recurrent CNAs were identified using GISTIC2.0. Associations with progression and overall survival (OS) were assessed using Cox proportional hazards models, including time-dependent analyses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Baseline TFx differed across metastatic disease stages (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.027) and dynamic TFx changes paralleled PSA kinetics during early treatment. Modelled as a time-dependent variable, TFx was associated with a significantly increased risk of progression (HR 4.9, 95% CI 1.2\u201320.1,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.026). Unsupervised clustering identified distinct high- and low-CNA burden groups strongly correlated with TFx (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20098.09\u2009\u00d7\u200910\u207b\n                      <jats:sup>8<\/jats:sup>\n                      ). High CNA burden was associated with shorter median OS (8.3 vs 13.8\u00a0months). Multivariable analysis identified baseline logPSA and logALP as independent predictors of OS. Recurrent CNAs affected key tumor suppressors (PTEN, RB1, BRCA2, ATM) and were enriched in pathways related to TP53 signalling, homologous recombination repair, and oncogenic signaling. Longitudinal analyses demonstrated persistence and expansion of specific amplifications at progression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ctDNA-derived TFx represents a dynamic biomarker of treatment response and progression risk, while CNA profiling provides insight into resistance mechanisms in mCRPC treated with PSMA-RLT. These findings support the integration of ctDNA-based biomarkers into clinical stratification and real-time monitoring strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16791-9","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:45:33Z","timestamp":1787993133000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of circulating tumor DNA and copy-number alterations in patients receiving tandem [225Ac]Ac-\/[177Lu]Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer: a prospective observational study"],"prefix":"10.1186","volume":"26","author":[{"given":"Mariam","family":"Amghar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hielscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Rausch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilal","family":"\u00d6zg\u00fcr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Bauder-W\u00fcst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Rathke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Bruchertseifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Morgenstern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareike","family":"Roscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladim\u00edr","family":"Bene\u0161","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Kratochwil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8926-5376","authenticated-orcid":false,"given":"Martina","family":"Bene\u0161ov\u00e1-Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"16791_CR1","doi-asserted-by":"crossref","unstructured":"Tannock IF, Wit Rd, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502\u201312.","DOI":"10.1056\/NEJMoa040720"},{"key":"16791_CR2","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424\u201333.","journal-title":"N Engl J Med"},{"key":"16791_CR3","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152\u201360.","journal-title":"Lancet Oncol"},{"key":"16791_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Foss\u00e5 SD, et al. Alpha Emitter Radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213\u201323.","journal-title":"N Engl J Med"},{"key":"16791_CR5","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J Bono","year":"2020","unstructured":"Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091\u2013102.","journal-title":"N Engl J Med"},{"key":"16791_CR6","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, De Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091.","journal-title":"N Engl J Med"},{"key":"16791_CR7","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, et al. (177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024;404:1227\u201339.","journal-title":"Lancet"},{"key":"16791_CR8","unstructured":"Novartis Pharma K.K. Novartis obtains approval for Pluvicto\u00ae as Japan's first targeted radioligand therapy for PSMA-positive metastatic castration-resistant prostate cancer ( in Japanese ). Novartis Pharma K.K.; 2025."},{"key":"16791_CR9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2021.03.004","volume":"80","author":"MS Sadaghiani","year":"2021","unstructured":"Sadaghiani MS, Sheikhbahaei S, Werner RA, Pienta KJ, Pomper MG, Solnes LB, et al. A systematic review and meta-analysis of the effectiveness and toxicities of Lutetium-177-labeled prostate-specific membrane antigen-targeted radioligand therapy in metastatic castration-resistant prostate cancer. Eur Urol. 2021;80:82\u201394.","journal-title":"Eur Urol"},{"key":"16791_CR10","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, et al. 225Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57:1941\u20134.","journal-title":"J Nucl Med"},{"key":"16791_CR11","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00259-019-04612-0","volume":"47","author":"F Khreish","year":"2020","unstructured":"Khreish F, Ebert N, Ries M, Maus S, Rosar F, Bohnenberger H, et al. (225)Ac-PSMA-617\/(177)Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imaging. 2020;47:721\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"16791_CR12","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2967\/jnumed.123.267206","volume":"65","author":"H Rathke","year":"2024","unstructured":"Rathke H, Winter E, Bruchertseifer F, R\u00f6hrich M, Giesel FL, Haberkorn U, et al. Deescalated (225)Ac-PSMA-617 Versus (177)Lu\/(225)Ac-PSMA-617 Cocktail Therapy: A Single-Center Retrospective Analysis of 233 Patients. J Nucl Med. 2024;65:1057\u201363.","journal-title":"J Nucl Med"},{"key":"16791_CR13","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1007\/s00259-020-04723-z","volume":"47","author":"J Ferdinandus","year":"2020","unstructured":"Ferdinandus J, Violet J, Sandhu S, Hicks RJ, Ravi Kumar AS, Iravani A, et al. Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617. Eur J Nucl Med Mol Imaging. 2020;47:2322\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"16791_CR14","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2967\/jnumed.119.231431","volume":"61","author":"H Rathke","year":"2020","unstructured":"Rathke H, Holland-Letz T, Mier W, Flechsig P, Mavriopoulou E, R\u00f6hrich M, et al. Response prediction of (177)Lu-PSMA-617 radioligand therapy using prostate-specific antigen, chromogranin A, and lactate dehydrogenase. J Nucl Med. 2020;61:689\u201395.","journal-title":"J Nucl Med"},{"key":"16791_CR15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13073-022-01080-4","volume":"14","author":"E Grist","year":"2022","unstructured":"Grist E, Friedrich S, Brawley C, Mendes L, Parry M, Ali A, et al. Accumulation of copy number alterations and clinical progression across advanced prostate cancer. Genome Med. 2022;14:102.","journal-title":"Genome Med"},{"key":"16791_CR16","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122109","volume":"3","author":"AD Choudhury","year":"2018","unstructured":"Choudhury AD, Werner L, Francini E, Wei XX, Ha G, Freeman SS, et al. Tumor fraction in cell-free DNA as a biomarker in prostate cancer. JCI Insight. 2018;3: e122109.","journal-title":"JCI Insight."},{"key":"16791_CR17","doi-asserted-by":"publisher","first-page":"4714","DOI":"10.3390\/cancers14194714","volume":"14","author":"J Huang","year":"2022","unstructured":"Huang J, Du M, Soupir A, Wang L, Tan W, Kalari KR, et al. Plasma copy number alteration-based prognostic and predictive multi-gene risk score in metastatic castration-resistant prostate cancer. Cancers (Basel). 2022;14:4714.","journal-title":"Cancers (Basel)"},{"key":"16791_CR18","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/s41467-017-00965-y","volume":"8","author":"VA Adalsteinsson","year":"2017","unstructured":"Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017;8:1324.","journal-title":"Nat Commun"},{"key":"16791_CR19","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13073-022-01080-4","volume":"14","author":"E Grist","year":"2022","unstructured":"Grist E, Friedrich S, Brawley C, Mendes L, Parry M, Ali A, et al. Accumulation of copy number alterations and clinical progression across advanced prostate cancer. Genome Medicine. 2022;14:102.","journal-title":"Genome Medicine"},{"key":"16791_CR20","doi-asserted-by":"crossref","unstructured":"Kwan EM, Fettke H, Bukczynska P, Ng N, Hauser C, Graham L-JK, et al. Plasma cell-free DNA (cfDNA) profiling of copy number variation (CNV) to identify poor prognostic biomarkers in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2020;38.","DOI":"10.1200\/JCO.2020.38.6_suppl.176"},{"key":"16791_CR21","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1158\/1078-0432.CCR-20-3345","volume":"27","author":"L Paracchini","year":"2021","unstructured":"Paracchini L, Beltrame L, Grassi T, Inglesi A, Fruscio R, Landoni F, et al. Genome-wide copy-number alterations in circulating tumor DNA as a novel biomarker for patients with high-grade serous ovarian cancer. Clin Cancer Res. 2021;27:2549\u201359.","journal-title":"Clin Cancer Res"},{"key":"16791_CR22","doi-asserted-by":"publisher","first-page":"e401","DOI":"10.1002\/ctm2.401","volume":"11","author":"K Gambaro","year":"2021","unstructured":"Gambaro K, Marques M, McNamara S, du Tertre MC, Diaz Z, Hoffert C, et al. Copy number and transcriptome alterations associated with metastatic lesion response to treatment in colorectal cancer. Clin Transl Med. 2021;11:e401.","journal-title":"Clin Transl Med"},{"key":"16791_CR23","doi-asserted-by":"publisher","first-page":"938985","DOI":"10.3389\/fgene.2022.938985","volume":"13","author":"M Sharbatoghli","year":"2022","unstructured":"Sharbatoghli M, Fattahi F, Es HA, Akbari A, Akhavan S, Ebrahimi M, et al. Copy number variation of circulating tumor DNA (ctDNA) detected using NIPT in neoadjuvant chemotherapy-treated ovarian cancer patients. Front Genet. 2022;13:938985.","journal-title":"Front Genet"},{"key":"16791_CR24","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1158\/1078-0432.CCR-18-1593","volume":"25","author":"X Chen","year":"2019","unstructured":"Chen X, Chang CW, Spoerke JM, Yoh KE, Kapoor V, Baudo C, et al. Low-pass whole-genome sequencing of circulating cell-free DNA demonstrates dynamic changes in genomic copy number in a squamous lung cancer clinical cohort. Clin Cancer Res. 2019;25:2254\u201363.","journal-title":"Clin Cancer Res"},{"key":"16791_CR25","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1373\/clinchem.2018.290023","volume":"64","author":"S Silva","year":"2018","unstructured":"Silva S, Danson S, Teare D, Taylor F, Bradford J, McDonagh AJG, et al. Genome-wide analysis of circulating cell-free DNA copy number detects active melanoma and predicts survival. Clin Chem. 2018;64:1338.","journal-title":"Clin Chem"},{"key":"16791_CR26","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2967\/jnumed.119.234559","volume":"61","author":"C Kratochwil","year":"2020","unstructured":"Kratochwil C, Giesel FL, Heussel CP, Kazdal D, Endris V, Nientiedt C, et al. Patients resistant against PSMA-targeting \u03b1-radiation therapy often harbor mutations in DNA damage-repair-associated genes. J Nucl Med. 2020;61:683\u20138.","journal-title":"J Nucl Med"},{"key":"16791_CR27","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/pros.24450","volume":"83","author":"S Satapathy","year":"2023","unstructured":"Satapathy S, Das CK, Aggarwal P, Sood A, Parihar AS, Singh SK, et al. Genomic characterization of metastatic castration-resistant prostate cancer patients undergoing PSMA radioligand therapy: A single-center experience. Prostate. 2023;83:169\u201378.","journal-title":"Prostate"},{"key":"16791_CR28","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.7150\/thno.96322","volume":"14","author":"PHJ Slootbeek","year":"2024","unstructured":"Slootbeek PHJ, Luna-Velez MV, Priv\u00e9 BM, van der Doelen MJ, Kloots ISH, Pamidimarri Naga S, et al. Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients. Theranostics. 2024;14:4555\u201369.","journal-title":"Theranostics"},{"key":"16791_CR29","doi-asserted-by":"publisher","first-page":"795","DOI":"10.2967\/jnumed.117.203539","volume":"59","author":"C Kratochwil","year":"2018","unstructured":"Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, et al. Targeted \u03b1-Therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J Nucl Med. 2018;59:795.","journal-title":"J Nucl Med"},{"key":"16791_CR30","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/biostatistics\/kxx039","volume":"19","author":"Y Fong","year":"2018","unstructured":"Fong Y, Huang Y, Lemos MP, McElrath MJ. Rank-based two-sample tests for paired data with missing values. Biostatistics. 2018;19:281\u201394.","journal-title":"Biostatistics"},{"key":"16791_CR31","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2307\/2533958","volume":"53","author":"NA Obuchowski","year":"1997","unstructured":"Obuchowski NA. Nonparametric analysis of clustered ROC curve data. Biometrics. 1997;53:567\u201378.","journal-title":"Biometrics"},{"issue":"4","key":"16791_CR32","doi-asserted-by":"publisher","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G, et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41.","journal-title":"Genome Biol"},{"key":"16791_CR33","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215\u201328.","journal-title":"Cell"},{"key":"16791_CR34","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13550-026-01388-x","volume":"16","author":"M Amghar","year":"2026","unstructured":"Amghar M, Rausch T, \u00d6zg\u00fcr H, Roscher M, Bauder-W\u00fcst U, Bruchertseifer F, et al. Exploratory case series of circulating tumor DNA dynamics during tandem therapy in metastatic castration-resistant prostate cancer. EJNMMI Res. 2026;16:43.","journal-title":"EJNMMI Res"},{"key":"16791_CR35","first-page":"11","volume":"29","author":"D Mishra","year":"2019","unstructured":"Mishra D, Banerjee D. Lactate Dehydrogenases as Metabolic Links between Tumor and Stroma in the Tumor Microenvironment. Cancers. 2019;29:11.","journal-title":"Cancers"},{"key":"16791_CR36","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1080\/02841860701644086","volume":"47","author":"S Lukacova","year":"2008","unstructured":"Lukacova S, S\u00f8rensen BS, Alsner J, Overgaard J, Horsman MR. The impact of hypoxia on the activity of lactate dehydrogenase in two different pre-clinical tumour models. Acta Oncol. 2008;47:941\u20137.","journal-title":"Acta Oncol"},{"issue":"2","key":"16791_CR37","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/pcan.2016.71","volume":"20","author":"AH Bryce","year":"2017","unstructured":"Bryce AH, Alumkal JJ, Armstrong A, Higano CS, Iversen P, Sternberg CN, et al. Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. Prostate Cancer Prostatic Dis. 2017;20(2):221.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"16791_CR38","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41391-020-0228-0","volume":"24","author":"R Aggarwal","year":"2021","unstructured":"Aggarwal R, Romero GR, Friedl V, Weinstein A, Foye A, Huang J, et al. Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer. Prostate Cancer Prostatic Dis. 2021;24:81\u20137.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"16791_CR39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.eururo.2025.08.015","volume":"90","author":"H Fettke","year":"2025","unstructured":"Fettke H, Kostos L, Docanto M, Bukczynska P, Ng N, Medhurst E, et al. Baseline and early on-treatment circulating tumour DNA fraction are a key prognostic biomarker in metastatic castration-resistant prostate cancer treated with [177Lu]Lu-PSMA-617. Eur Urol. 2025;90:74.","journal-title":"Eur Urol"},{"key":"16791_CR40","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/ijc.31397","volume":"143","author":"J Belic","year":"2018","unstructured":"Belic J, Graf R, Bauernhofer T, Cherkas Y, Ulz P, Waldispuehl-Geigl J, et al. Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. Int J Cancer. 2018;143:1236.","journal-title":"Int J Cancer"},{"key":"16791_CR41","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1038\/s41416-021-01508-5","volume":"125","author":"U De Giorgi","year":"2021","unstructured":"De Giorgi U, Sansovini M, Severi S, Nicolini S, Monti M, Gurioli G, et al. Circulating androgen receptor gene amplification and resistance to (177)Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial. Br J Cancer. 2021;125:1226\u201332.","journal-title":"Br J Cancer"},{"key":"16791_CR42","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.euros.2023.05.008","volume":"53","author":"J Vanwelkenhuyzen","year":"2023","unstructured":"Vanwelkenhuyzen J, Van Bos E, Van Bruwaene S, Lesage K, Maes A, \u00dcstmert S, et al. AR and PI3K Genomic Profiling of Cell-free DNA Can Identify Poor Responders to Lutetium-177-PSMA Among Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol Open Sci. 2023;53:63\u20136.","journal-title":"Eur Urol Open Sci"},{"key":"16791_CR43","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00259-018-4167-0","volume":"46","author":"M Sathekge","year":"2019","unstructured":"Sathekge M, Bruchertseifer F, Knoesen O, Reyneke F, Lawal I, Lengana T, et al. (225)Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2019;46:129\u201338.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"16791_CR44","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","volume":"25","author":"MM Sathekge","year":"2024","unstructured":"Sathekge MM, Lawal IO, Bal C, Bruchertseifer F, Ballal S, Cardaci G, et al. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study. Lancet Oncol. 2024;25:175\u201383.","journal-title":"Lancet Oncol"},{"key":"16791_CR45","doi-asserted-by":"publisher","first-page":"e0307826","DOI":"10.1371\/journal.pone.0307826","volume":"19","author":"T Zhang","year":"2024","unstructured":"Zhang T, Li W, Wei H, Huang Z, Yang J, Zeng H, et al. Prognostic value of baseline alkaline phosphatase of 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. PLoS ONE. 2024;19:e0307826.","journal-title":"PLoS ONE"},{"key":"16791_CR46","doi-asserted-by":"publisher","first-page":"103108","DOI":"10.18632\/oncotarget.21600","volume":"8","author":"H Ahmadzadehfar","year":"2017","unstructured":"Ahmadzadehfar H, Schlolaut S, Fimmers R, Yordanova A, Hirzebruch S, Schlenkhoff C, et al. Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [(177)Lu]Lu-PSMA-617 radioligand therapy. Oncotarget. 2017;8:103108\u201316.","journal-title":"Oncotarget"},{"key":"16791_CR47","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.7150\/thno.109860","volume":"15","author":"N Poterszman","year":"2025","unstructured":"Poterszman N, Hammer-Lefevre C, Porot C, Salvadori J, Barth\u00e9l\u00e9my P, Somme F. Visceral metastases, platelet dynamics, and PSA decline: from biomarkers to better outcomes in [177Lu]Lu-PSMA-617 therapy in metastatic castration-resistant prostate cancer. Theranostics. 2025;15:3724\u201332.","journal-title":"Theranostics"},{"key":"16791_CR48","first-page":"41","volume":"15","author":"M Alshalafa","year":"2022","unstructured":"Alshalafa M, Nguyen T, Stopsack K, Khan A, Franco I, Seldon C, et al. Chromosome 8q arm overexpression is associated with worse prostate cancer prognosis. Urol Oncol. 2022;15:41.","journal-title":"Urol Oncol"},{"issue":"1","key":"16791_CR49","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12920-020-00765-2","volume":"13","author":"Y Chen","year":"2020","unstructured":"Chen Y, Sadasivan SM, She R, Datta I, Taneja K, Chitale D, et al. Breast and prostate cancers harbor common somatic copy number alterations that consistently differ by race and are associated with survival. BMC Med Genomics. 2020;13(1):116.","journal-title":"BMC Med Genomics"},{"key":"16791_CR50","doi-asserted-by":"publisher","first-page":"1741080","DOI":"10.3389\/fonc.2026.1741080","volume":"16","author":"M Amghar","year":"2026","unstructured":"Amghar M, Roscher M, Rausch T, \u00d6zg\u00fcr H, Bauder-W\u00fcst U, Bruchertseifer F, et al. Genomic analysis in chemotherapy-na\u00efve prostate cancer prior to PSMA-targeted treatment. Front Oncol. 2026;16:1741080.","journal-title":"Front Oncol"},{"key":"16791_CR51","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1158\/1078-0432.CCR-22-0931","volume":"29","author":"KN Chi","year":"2023","unstructured":"Chi KN, Barnicle A, Sibilla C, Lai Z, Corcoran C, Barrett JC, et al. Detection of BRCA1, BRCA2, and ATM alterations in matched tumor tissue and circulating tumor DNA in patients with prostate cancer screened in PROfound. Clin Cancer Res. 2023;29:81\u201391.","journal-title":"Clin Cancer Res"},{"key":"16791_CR52","doi-asserted-by":"publisher","first-page":"729 e7","DOI":"10.1016\/j.urolonc.2020.12.002","volume":"39","author":"MJ van der Doelen","year":"2021","unstructured":"van der Doelen MJ, Mehra N, van Oort IM, Looijen-Salamon MG, Janssen MJR, Custers JAE, et al. Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy. Urol Oncol. 2021;39:729 e7-e16.","journal-title":"Urol Oncol"},{"key":"16791_CR53","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.eururo.2018.09.040","volume":"76","author":"PI Velho","year":"2019","unstructured":"Velho PI, Qazi F, Hassan S, Carducci MA, Denmeade SR, Markowski MC, et al. Efficacy of Radium-223 in bone-metastatic castration-resistant prostate cancer with and without homologous repair gene defects. Eur Urol. 2019;76:170.","journal-title":"Eur Urol"},{"key":"16791_CR54","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","volume":"76","author":"A Paschalis","year":"2019","unstructured":"Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, et al. Prostate-specific Membrane antigen heterogeneity and DNA Repair defects in prostate cancer. Eur Urol. 2019;76:469.","journal-title":"Eur Urol."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16791-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16791-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16791-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:30:37Z","timestamp":1788244237000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16791-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16791"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16791-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9737806\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]},"assertion":[{"value":"17 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study received ethical approval (S-882\/2020) from the Ethics Committee of the Medical Faculty at Heidelberg University. This project is a non-interventional, exploratory investigation focusing on therapy resistance in patients treated with [\n                      225\n                      Ac]Ac-\/[\n                      177\n                      Lu]Lu-PSMA-617. The study complies with national regulations, the Declaration of Helsinki, and Good Clinical Practice (GCP) guidelines. Furthermore, in accordance with Paragraph 13(2b) of the German Pharmaceuticals Law, the therapy was administered as a salvage treatment for patients with mCRPC who had progressive disease and were either resistant to or ineligible for approved therapeutic options.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A patent application for PSMA-617 has been filed by the German Cancer Research Center (DKFZ) and the University Clinic Heidelberg (UKHD). Ulrike Bauder-W\u00fcst, Clemens Kratochwil, and Martina Bene\u0161ov\u00e1-Sch\u00e4fer are co-inventors of this patent.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1038"}}